Christine D. Baker
Christine Baker was appointed Chief Operating Officer in May 2022. Christine is responsible for the company’s Clinical Operations and Regulatory Affairs teams as well as Business Development, Alliance Management, Intellectual Property, Commercial Strategy and the New York City site. At HOOKIPA, Christine’s notable Business Development include the Roche KRAS licensing collaboration in October 2022, the Gilead HIV renegotiation in February 2022, and the Merck clinical collaboration in September 2021. Christine has more than 30 years of experience with biopharma innovation. Christine joined Hookipa in August 2019 as Chief Business Officer. Prior to joining Hookipa, she was Chief Business Officer at EpicentRx, where she led the partnering activities for multiple clinical-stage oncology assets. Before this, as a Vice President at Novartis, she was a leader in Oncology business development and M&A; high profile accomplishments included the $16 billion multi-asset swap between Novartis and Glaxo SmithKline in 2014 and the collaboration with the University of Pennsylvania in 2012 which led to the first-in-class chimeric antigen receptor T-cell (CAR-T) therapy. In creating the Early Commercial Strategy unit, Christine built a team which worked closely with R&D colleagues to optimize product differentiation and future commercial performance. Christine began her career in Schering-Plough, where she made notable contributions in Research Licensing, Strategic Planning and multiple US and Global Commercial roles, including acting Vice President for Sales and Marketing. Christine earned her undergraduate Chemistry degree magna cum laude from Dartmouth College and an MBA from Rutgers University. She has served as a non-executive director on the Boards of TYME Technologies and TuHURA Biopharma, Inc.